Compumedics Limited (ASX:CMP) Achieves Record Sales and Returns to Profitability
Record Sales Orders Drive Growth
Compumedics Limited reported record sales orders of $63.4 million for FY25, a 22% increase from FY24. The Sleep & Neurology segment saw orders rise by 39% to $53.0 million, driven by a 102% growth in US Sleep Diagnostics to $23.5 million. Somfit and Nexus 360 SaaS orders increased by 49% to $6.7 million, with US Somfit sales orders soaring 675% from $0.4 million to $3.1 million. Additionally, MEG orders reached $5.9 million, with three systems expected to contribute approximately $15 million in revenue for FY26. Geographically, the US led growth with a 115% increase in sales orders, followed by Asia at 71% and Europe at 12%.
Revenue and Profitability Improve
The company reported unaudited revenue of $51.0 million for FY25, a 4% increase from FY24. The Sleep & Neurology segment contributed $46.3 million, up 16%, while the Somfit and Nexus 360 SaaS segment generated $6.0 million, a 41% increase. EBITDA rose to approximately $3 million, signalling a return to profitability. This margin improvement was driven by product mix optimisation, scaling of SaaS, and stable overheads. A modest $4.1 million capital raise was used to cover expanded working capital needs.
Strong Outlook for FY26
Compumedics reaffirmed its FY26F guidance with expected revenue of at least $70 million and EBITDA of approximately $9 million. The SaaS and connected platforms are projected to contribute over 20% of group revenue, offering high margins and scalability. The launch of disposable Somfit (Somfit D) in the US aims to capture a significant share of the 3-4 million unit annual Home Sleep Test market, valued between $150 million and $300 million. Three MEG systems are on track for FY26 revenue, with expansion into the paediatric market increasing the MEG opportunity to around $120 million. The company remains focused on commercial execution, margin optimisation, and capital efficiency.
Executive Comments
Executive Chairman Dr. David Burton commented, “This result reflects the step-change underway at Compumedics. We are building a more predictable, higher-margin business model and seeing consistent revenue growth, expanding margins, and meaningful traction in the US and across our connected platforms. FY26 will see us scale into a more focused, cash-generative global business underpinned by recurring revenues from Somfit and clinical innovation, with MEG deliveries and growing demand in China providing further upside.”
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
